CHONGQING TAIJI INDUSTRY(GROUP) CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.38 CNY | -2.32% |
|
-2.00% | -30.31% |
| Sales 2024 * | 17.82B 2.46B | Sales 2025 * | 22.08B 3.05B | Capitalization | 18.03B 2.49B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.08B 149M | Net income 2025 * | 1.46B 202M | EV / Sales 2024 * | 1.01 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.82 x |
| P/E ratio 2024 * |
16.7
x | P/E ratio 2025 * |
12.3
x | Employees | 12,589 |
| Yield 2024 * |
1.02% | Yield 2025 * |
1.76% | Free-Float | 61.27% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.32% | ||
| 1 week | -2.00% | ||
| Current month | -2.62% | ||
| 1 month | -15.43% | ||
| 3 months | -18.99% | ||
| 6 months | -16.07% | ||
| Current year | -30.31% |
1 week
31.71
33.55
1 month
31.3036.40
Current year
29.7550.33
1 year
29.7568.44
3 years
14.2468.44
5 years
9.0868.44
10 years
7.8168.44
| Managers | Title | Age | Since |
|---|---|---|---|
Min Yu
CEO | Chief Executive Officer | 51 | 21-05-18 |
Zun Yi Liu
DFI | Director of Finance/CFO | 53 | - |
Wang Xu
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Chun Wang
BRD | Director/Board Member | 56 | 21-05-18 |
Ling Shen
BRD | Director/Board Member | 63 | 21-05-18 |
Qian Jiang
SEC | Corporate Secretary | 52 | 18-05-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 32.38 | -2.32% | 11,747,690 |
| 24-04-17 | 33.15 | +4.05% | 14,343,590 |
| 24-04-16 | 31.86 | -3.63% | 12,321,310 |
| 24-04-15 | 33.06 | +2.45% | 16,021,220 |
| 24-04-12 | 32.27 | -2.33% | 10,719,810 |
End-of-day quote Shanghai S.E., April 17, 2024
More quotes
CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD. is a China-based company principally engaged in the production and sales of Chinese and Western medicines. The Company is also engaged in the cultivation of medicinal herbs. The Company's products mainly include capsules, syrup, oral liquid, lyophilized series, tablets, infusion series and injections. The Company mainly conducts its business in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.38
CNY
Average target price
52.83
CNY
Spread / Average Target
+63.16%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.31% | 2.49B | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 600129 Stock
